Education
About Us
Working with TipRanks
Follow Us
Cybin (TSE:CYBN)
NEO-L:CYBN
CYBN Stock Chart & Stats
C$0.14
-C$0.50(-3.50%)
At close: 4:00 PM EST
C$0.14
-C$0.50(-3.50%)
Day’s Range― - ―
52-Week RangeC$0.14 - C$0.14
Previous CloseN/A
Volume13.54K
Average Volume (3M)0.00
Market Cap
C$1.92M
Enterprise ValueC$0.00
Total Cash (Recent Filing)C$116.53M
Total Debt (Recent Filing)C$40.19M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Feb 17, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding49,894,130
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$62.03Price Target Upside44210.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSteady progress across both late-stage programs, with CYB004 Phase 2a enrollment complete and top-line data expected in the first quarter, and CYB003 advancing through the Phase 3 PARADIGM program under Breakthrough Therapy Designation.
Financial StabilityCybin raised $175 million through a registered direct financing, combined with cash of $83.8 million at the end of F2Q26, Cybin's runway extends into 2027, through multiple key data readouts.
Leadership And ManagementThe board is actively searching for a new CEO following a leadership transition, reinforcing management’s focus on operational rigor and execution as the company approaches a significant clinical year.
Bears Say
Financial ProjectionsThe increased share count from the recent financing, normalization of expenses in the model, and fine-tuning the expected CYB003 and CYB004 launches resulted in a revised $55 price target from $150.
Stock Price TargetThe updated model includes a reduced price target from $70 to $45, mainly due to dilution from the recent capital raise.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is C$1.92M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 17, 2026 which is in 60 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 13, 2025. The company reported -C$1.947 earnings per share for the quarter, missing the consensus estimate of -C$1.455 by -C$0.492.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.81.
How many shares outstanding does Cybin have?
Cybin has 49,894,130 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -C$1.947 in its last earnings report, missing expectations of -C$1.455. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in TSE:CYBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cybin
Cybin (CYBN) is a biotechnology company focused on advancing psychedelic therapeutics for mental health disorders. Operating primarily in the pharmaceutical sector, Cybin is dedicated to the research and development of psychedelic compounds, aiming to improve patient outcomes through novel drug formulations and delivery systems. The company's core services include clinical trials, drug development, and partnerships with research institutions to explore the therapeutic potential of psychedelics.
CYBN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all TSE:CYBN earnings summariesCYBN Stock 12 Month Forecast
Average Price Target
C$62.03
▲(44210.22% Upside)
Technical Analysis
Restart Life Sciences
―
Waverley Pharma
―
MYND Life Sciences
―
―
Doseology Sciences
―
Options Prices
Currently, No data available
---